You have 9 free searches left this month | for more free features.

High-Risk Myelodysplastic Syndrome

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Sep 18, 2023

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial

Recruiting
  • Recurrent Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)

Recruiting
  • Myelodysplastic Syndromes
  • 50 gm CIVI/24 hours x 5 days every 4 week
  • Miami, Florida
  • +1 more
Jul 6, 2022

Acute Myeloid Leukemia, MDS Trial (SPRX002, ARC-T)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • SPRX002
  • ARC-T
  • (no location specified)
Jul 12, 2022

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte, New York, Houston (BTX-A51)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Duarte, California
  • +2 more
Sep 8, 2022

Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)

Recruiting
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 23, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Sacramento (Lenalidomide)

Completed
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Sacramento, California
    University of California Davis
Mar 8, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial

Completed
  • Relapsed Acute Myeloid Leukemia (AML)
  • +2 more
  • Atlanta, Georgia
  • +5 more
Apr 4, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome Trial (VIP943)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • (no location specified)
Sep 5, 2023

Leukemia, Myeloid, Acute Trial in Japan (Cusatuzumab, Azacitidine)

Completed
  • Leukemia, Myeloid, Acute
  • Fukushima, Japan
  • +4 more
Aug 8, 2022

Leukemia Trial in Houston (Vosaroxin, Decitabine)

Completed
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 13, 2022

Leukemia, Acute, AML, Adult, ALL, Adult Trial in Charlottesville (Palliative Care Visits)

Recruiting
  • Leukemia, Acute
  • +3 more
  • Palliative Care Visits
  • Charlottesville, Virginia
    University of Virginia
Apr 28, 2022

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid

Active, not recruiting
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +9 more
  • Sewell, New Jersey
  • +4 more
Dec 13, 2022

Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Baltimore, Maryland
  • +2 more
Feb 25, 2022

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023